Dragon Announces Appointment of General Manager of Chinese Operations

News

Dragon Pharmaceutical Inc. (OTC BB: DRUG; TSX: DDD) today announced the appointment of Mr. Xiaochun Zhang as the General Manager of the Company’s Chinese operations.

As the General Manager of our Chinese operations, Mr. Zhang is responsible for the overall operational and sales and marketing management of the Pharma and Chemical divisions. Such responsibilities will be extended to cover the Biotech division after its relocation from its current location in Nanjing city.

Mr. Zhang has 20 years of expertise in large-scale fermentation processes as a chemical engineer together with operational experience with various Chinese and international pharmaceutical companies. Prior to joining Dragon, Mr. Zhang was the Deputy General Manager of Aurobindo Bio-pharma Co. Ltd. in Datong, China, a subsidiary of one of the largest pharmaceutical companies in India. Mr. Zhang started his career as an engineer in the fermentation workshop in Zhangjiakou Pharmaceutical Co. Ltd., and became the Deputy General Manager of the company in 1997. In the same year, Mr. Zhang was appointed as the General Manager of GIST-Brocades Pharmaceutical Ltd., a joint venture in China between Zhangjiakou Pharmaceutical Co. Ltd. and Netherlands?DSM, one of largest chemical companies in the world.

Mr. Zhang holds a Bachelor degree in chemical mechanical engineering from Hebei University of Technology and is currently participating in an Executive MBA program from the Helsinki School of Economics and Business Administration. Mr. Zhang is based in our office in Datong city, China.

Dragon Pharma Reviews

Dragon Pharma operates four separate pharmacy businesses from its location in Europe. They offer in-store and mail order steroids: Proviron for Sale.

No Tags

2323 total views, 1 today

Popular
Comments
Tags

Dragon Ships EPO Internationally

Dragon Pharmaceuticals Inc. (NASDAQ OTC: DRUG) today announced that it has filled orders for recombinant erythropoietin (EPO) from Egypt, India and Peru where, in addition to China, the Company’s EPO is approved for use in the treatment of anemia related to chronic renal failure. All dollar amounts are stated in US dollars. “Penetrating new markets […]
Dragon Pharmaceutical Inc. Announces 2002 Fourth Quarter and Full Year Results

Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG) today announced results for the three-month and twelve-month periods ending December 31, 2002. 2002 Highlights Generated revenues of $7.36 million, representing significant growth from $3.07 million in 2001. Enhancement of gross margin in 2002 to 86.7% from 81% in 2001. Reported a first ever operating profit of […]
Dragon Announces Participation at Biopartnering Europe 2001

Dragon Pharmaceuticals Inc. (OTC BB – DRUG.OB) is pleased to announce that it has been invited to present at the BioPartnering Europe 2001 conference to be held at the Queen Elizabeth II Conference Centre in London, England from October 14th to 16th, 2001. BioPartnering Europe is the premier European venue for showcasing innovative biopharmaceutical and […]
Dragon Launches EPO Into the Brazilian Market

Dragon Pharmaceuticals Inc. (OTC BB: DRUG; TSX: DDD) today announced that it has shipped an order of recombinant erythropoietin (“EPO? to Itaca Laboratorios Ltda., (“Itaca” of Brazil. Itaca, a distribution partner of the company, has won a 3.1 million Brazilian Real tender for Dragon’s EPO in the Brazilian state of Minas, Gerais, which converts to […]
Dragon Signs Licensing Agreement for Korea

Dragon Pharmaceuticals Inc. (OTCBB – DRUG.OB) today announced that it has entered into a marketing and licensing agreement with Boryung Biopharma Company, Ltd. of Seoul, Korea for the distribution of recombinant Erythropoietin (EPO) in North and South Korea. According to the agreement, Boryung Biopharma will also be responsible for obtaining marketing for EPO from the […]